NCT05283746View on ClinicalTrials.gov

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

June 10, 2022

Study Completion Date

June 27, 2022

Conditions
Renal Insufficiency
Interventions
DRUG

Epetraborole

Epetraborole hydrochloride 250 mg tablets for oral administration

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33147

Advanced Pharma CR, Miami

55114

Nucleus Network, Saint Paul

Sponsors
All Listed Sponsors
lead

AN2 Therapeutics, Inc

INDUSTRY

NCT05283746 - A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function | Biotech Hunter | Biotech Hunter